Reassessing Incyte (INCY) Valuation After Wells Fargo's Neutral Downgrade [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
Wells Fargo's recent downgrade of Incyte (INCY) to a more neutral rating, citing already realized positives and limited near term catalysts, has prompted investors to reassess what will drive the stock from this point forward. See our latest analysis for Incyte. The Wells Fargo downgrade comes after a strong run, with a 16.53% 90 day share price return and a 39.68% 1 year total shareholder return. This suggests earlier optimism has already been reflected, while shorter term momentum has cooled. If you are looking beyond a single biopharma name, this could be a good moment to scan other US healthcare stocks for different risk and growth profiles. With Incyte now trading almost in line with the latest analyst target and showing a very high intrinsic value score, the key question is whether the recent strength leaves the shares fully priced or if the market is still underestimating future growth. Incyte is trading on a P/E of 17x, compared with peer and sector averages closer
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte (INCY) Q4 Earnings: What To Expect [Yahoo! Finance]Yahoo! Finance
- Incyte (NASDAQ:INCY) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029 [Yahoo! Finance]Yahoo! Finance
- Incyte (NASDAQ:INCY) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $135.00 price target on the stock.MarketBeat
- Analysts Differ in Opinion on Jakafi Drug Maker Incyte (INCY) [Yahoo! Finance]Yahoo! Finance
INCY
Earnings
- 10/28/25 - Beat
INCY
Sec Filings
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- 1/21/26 - Form 4
- INCY's page on the SEC website